ADepTing to the UCB-Novartis deal

ADepTing to the UCB-Novartis deal
# # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine ... read more
Source: The Science of Parkinson’s diseasePublished on 2021-12-06By Simon